Crispr Therapeutics (NASDAQ:CRSP)‘s stock had its “hold” rating restated by equities research analysts at Oppenheimer in a report released on Thursday, December 21st. CRSP has been the subject of a number of other research reports. Cann reiterated a “hold” rating on shares of Crispr Therapeutics in a research report on Sunday, December 10th. BidaskClub downgraded […]

Piper Jaffray Companies initiated coverage on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research report report published on Friday, December 22nd, Marketbeat reports. The brokerage issued an overweight rating on the stock. Several other analysts have also recently issued reports on the stock. Oppenheimer reaffirmed a hold rating on shares of Crispr Therapeutics in a […]

Rosetta Genomics (ROSG) & Crispr Therapeutics (CRSP) Head to Head Comparison

January 16, 2018 – By Darrin Black The stock of CRISPR Therapeutics AG (NASDAQ:CRSP) is a huge mover today! The stock decreased 6.38% or $1.8196 during the last trading session, reaching $26.7004. About 417,332 shares traded. CRISPR Therapeutics AG (NASDAQ:CRSP) has 0.00% since January 16, 2017 and is . It has underperformed by 16.70% the […]

Frederic J. Brown/AFP/Getty Images Alison Van Eenennaam’s lab at the University of California at Davis is using CRISPR technology to improve beef production. Introducing the SRY gene to the X chromosome of males essentially turns their female offspring into bulls, which grow faster and larger than cows, but those offspring are expected to be sterile […]

CRISPR Therapeutics AG (CRSP) Stock Price Movement: In recent trading day CRISPR Therapeutics AG (CRSP) stock showed the move of 0.28% with the closing price of $28.52. Closing price generally refers to the last price at which a stock trades during a regular trading session. The company moved in the past week with shift of […]

Shares of Crispr Therapeutics Ag (CRSP) is moving on volatility today -3.19% or -0.91 from the open. The NASDAQ listed company saw a recent bid of 27.605 on 297935 volume. Investors might be looking to find some bargains to add to the portfolio as we move closer towards the end of the year. Maybe some of the earlier portfolio picks don’t look […]

Today could play a pivotal role in the CRISPR patent landscape in Europe. The European Patent Office’s (EPO) Opposition Division has begun its oral hearing into the eligibility of one of ten European patents covering CRISPR/Cas9 technology that has been issued to the Broad Institute of MIT and Harvard. In April last year, the EPO […]

To paraphrase Mark Twain, the reports of the deaths of CRISPR gene-editing stocks are greatly exaggerated.  The biotech world was abuzz a little over a week ago with news that the human immune system has built-in defense systems against the Cas9 enzyme used in the CRISPR-Cas9 approach to gene editing. The CRISPR-Cas9 method has revolutionized […]

Crispr Therapeutics AG (NASDAQ:CRSP) saw unusually large options trading activity on Thursday. Stock investors acquired 1,168 put options on the stock. This represents an increase of 1,986% compared to the average volume of 56 put options. Several equities analysts recently issued reports on the stock. Piper Jaffray Companies reissued a “buy” rating and set a […]